Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 18/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | ALDH1A2 | O94788 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | ALDH1B1 | P30837 | 1/20 | 0.44 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7602694 | 0.93 | HRH3 (0.58) | HRH3MEN1KMT2AALDH1A2ALDH1A1 | |
| SCHEMBL7600623 | 0.87 | HRH3 (0.67) | HRH3KCNH2 | |
| SCHEMBL7597889 | 0.86 | HRH3 (0.67) | HRH3KCNH2 | |
| SCHEMBL7602672 | 0.80 | HRH3 (0.65) | HRH3ALDH1A1KCNH2 | |
| SCHEMBL2785367 | 0.79 | HRH3 (0.57) | HRH3KCNH2 | |
| SCHEMBL7601498 | 0.79 | HRH3 (0.64) | HRH3KCNH2 | |
| SCHEMBL2785371 | 0.79 | HRH3 (0.58) | HRH3ALDH1A2ALDH1A1ALDH2MAPT | |
| SCHEMBL7597675 | 0.77 | HRH3 (0.98) | HRH3 | |
| SCHEMBL2786426 | 0.77 | HSD17B3 (0.53) | MEN1KMT2AALDH1A2ALDH1A1ALDH2 | |
| SCHEMBL2785133 | 0.76 | HRH3 (1.00) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020183309-A1 | Novel amines as histamine-3 receptor ligands and their therapeutic applications | ABBOTT LABORATORIES | 2002-12-05 | — | — | US | disclosed |
| US-20020177589-A1 | Novel amines as histamine-3 receptor ligands and their therapeutic applications | ABBOTT LABORATORIES | 2002-11-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020177589-A1 | Novel amines as histamine-3 receptor ligands and their therapeutic applications | HRH3, HRH4, HRH1 | HRH3 1/4885MEN1 1036/4885KMT2A 1654/4885 |
| US-20020183309-A1 | Novel amines as histamine-3 receptor ligands and their therapeutic applications | HRH3, HRH4, HRH1 | HRH3 1/4885MEN1 1036/4885KMT2A 1654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.